Literature DB >> 3153270

Cyclosporin A in children with persistent renal transplant rejection and progressively deteriorating graft function.

D F Geary1, P Thorner, R Baumal, M Major, G Arbus.   

Abstract

The effect on renal function and growth of switching from azathioprine to cyclosporin A (CyA) was prospectively evaluated in ten children with persistent renal transplant rejection. Progression of renal insufficiency during CyA therapy was compared with that before using CyA. Prednisone administration decreased after CyA was introduced and although growth retardation persisted, height velocity improved significantly. Renal function stabilized in seven patients treated with CyA for a variable time period, and four of these children remain off dialysis 0.44-1.42 years later. Renal biopsies were obtained in seven children when they were converted from azathioprine to CyA. The response to CyA could not be predicted from renal morphology or clinical features.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3153270     DOI: 10.1007/bf00849284

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

1.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

2.  Combined report on regular dialysis and transplantation of children in Europe XII, 1982.

Authors:  M Broyer; R A Donckerwolcke; F P Brunner; H Brynger; S Challah; N Gretz; C Jacobs; P Kramer; N H Selwood; A J Wing
Journal:  Proc Eur Dial Transplant Assoc       Date:  1983

3.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-12       Impact factor: 3.791

4.  Dosage of Cyclosporin A in children with renal transplants.

Authors:  P F Hoyer; G Offner; K Wonigeit; J Brodehl; R Pichlmayr
Journal:  Clin Nephrol       Date:  1984-08       Impact factor: 0.975

5.  Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal.

Authors:  D F Geary; M Farine; P Thorner; R Baumal
Journal:  Clin Nephrol       Date:  1984-09       Impact factor: 0.975

6.  Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial.

Authors: 
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

7.  Method for predicting when children with progressive renal disease may reach high serum creatinine levels.

Authors:  G S Arbus; G S Bacheyie
Journal:  Pediatrics       Date:  1981-06       Impact factor: 7.124

8.  Cyclosporine in treatment of corticosteroid-resistant episodes of rejection.

Authors:  P Häyry; E von Willebrand; E Taskinen; J Ahonen; B Eklund; K Höckerstedt; E Petterson; H Sarelin
Journal:  Arch Surg       Date:  1983-06

9.  Use of cyclosporine in pediatric renal transplant recipients.

Authors:  S B Conley; S M Flechner; G Rose; C T Van Buren; E Brewer; B D Kahan
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

10.  A randomized clinical trial of cyclosporine in cadaveric renal transplantation.

Authors: 
Journal:  N Engl J Med       Date:  1983-10-06       Impact factor: 91.245

  10 in total
  3 in total

Review 1.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

3.  Characteristics of cadaveric renal allograft recipients developing chronic rejection.

Authors:  M C Foster; P A Rowe; M J Dennis; A G Morgan; R P Burden; R W Blamey
Journal:  Ann R Coll Surg Engl       Date:  1990-01       Impact factor: 1.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.